Economic consulting firm CRA International (NASDAQ: CRAI) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 10.5% year on year to $201 million. Its non-GAAP profit of $1.99 per share was 1.6% below analysts’ consensus estimates.

Is now the time to buy CRAI? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

CRA International’s first quarter was marked by robust revenue expansion, with the company benefiting from strong demand across several practices and geographies. Management highlighted that eight practices grew year-over-year, with Energy, Finance, Forensic Services, and Life Sciences all delivering double-digit growth. CEO Paul Maleh noted, “We generated growth across our geographies with our North American operations increasing revenue by 8.5% and our international operations expanding 20.3% year-over-year.” However, the quarter also saw significant margin compression, driven largely by increased forgivable loan amortization and higher employee-related costs.

Looking forward, CRA’s management remains optimistic about ongoing market demand and the company’s ability to capitalize on growth opportunities, but also acknowledged potential challenges from evolving macroeconomic and geopolitical conditions. Maleh emphasized the importance of expert-driven services, stating, “Clients hire us because they are dealing with situations in which expert insights can have profound financial and strategic impact.” The company intends to redeploy cost savings from recent restructuring back into talent investments, while pricing initiatives and complex project demand are expected to support future performance.

Key Insights from Management’s Remarks

Management attributed the quarter’s revenue growth to broad-based practice strength, robust project pipelines, and higher consultant utilization, but margins came under pressure from increased talent-related costs and restructuring charges.

• Broad-based practice momentum: Eight practices posted year-over-year revenue growth, with Energy, Finance, Forensic Services, and Life Sciences each achieving double-digit gains. Antitrust & Competition Economics delivered a record quarter, benefiting from heightened M&A activity and regulatory demand.

• Geographic expansion: International operations outpaced North America, growing over 20% year-over-year, driven by strong performance in European Life Sciences and Antitrust practices. Management noted that European growth was a key contributor to the quarter’s overall expansion.

• Consultant utilization and hiring: Utilization improved to 77% while headcount rose 2.5%. Management credited a robust sales pipeline and record project origination, which fueled the need for additional consultants and underpinned top-line growth.

• Talent investments and restructuring: CRA increased spending on senior revenue-generating talent and incurred a $2.6 million restructuring charge affecting 22 employees. The company expects annual cost savings of approximately $5 million, with plans to reinvest these savings into further talent acquisition to support long-term growth.

• Margin compression factors: Non-GAAP EBITDA margin was pressured by higher forgivable loan amortization, which increased 53% year-over-year to $13.8 million (6.9% of revenue). Management emphasized this cost is consistent with expectations and intended to support future talent ramp-up, but contributed to the decline in operating margin.

Drivers of Future Performance

CRA’s outlook is shaped by ongoing strength in project demand, continued hiring, and the redeployment of cost savings, though macroeconomic uncertainties present potential risks to margin recovery.

• Sustained project pipeline: Management expects continued high demand for expert-driven consulting, particularly in complex regulatory, legal, and M&A-related areas. The replenished project pipeline and robust lead flow are set to drive revenue, with utilization goals remaining in the upper-70% range.

• Talent acquisition and pricing: CRA plans to reinvest cost savings from recent restructuring into hiring experienced consultants and maintaining competitive compensation. Modest rate increases are expected to further support revenue growth, as new projects carry higher billing rates through the year.

• Margin headwinds and economic risk: While management is confident in the demand environment, they cautioned that higher employee and incentive costs, as well as broader geopolitical and macroeconomic challenges, could weigh on margins. The company is focused on maintaining profitability while navigating these uncertainties.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will closely watch (1) the pace of new project origination and whether consultant utilization remains at targeted levels, (2) the impact of talent investments and restructuring on overall margin recovery and cost efficiency, and (3) success in passing through rate increases as more projects onboard at higher billing rates. The ability to maintain momentum in European and high-growth practices will also be key signposts.

CRA currently trades at $138.25, down from $152.64 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

High Quality Stocks for All Market Conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.